Stock & Company Details
TG Therapeutics Inc $TGTX
Price:
N/A
N/A
153M
$8.5B
52 Week High:
N/A
10 Day Average Volume:
N/A
19.64
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
TGTX technical indicators
Latest TG Therapeutics Inc (TGTX) indicator readings as of 2026-08-28.
TGTX's 14-day RSI is 54.8, in neutral territory. At $53.93 it is trading 40.5% above its 200-day moving average of $38.39, and above its 50-day average of $53.37. Price sits in the middle of its Bollinger Bands ($45.40 to $56.75). ADX reads 23.6, sitting between trending and range-bound.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Finance Bot
Ask your questions
Start by typing a question below.
